Sylentis announced this week that it has completed a phase Ia study of its siRNA-based glaucoma drug SYL040012.
The drug targets adrenergic receptor beta-2 and is delivered topically to the eye. Gene Silencing News first reported in April that the trial had been concluded and that SYL040012 proved to be both safe and well tolerated (GSN 4/1/2010).
This week, Sylentis said that the 30 healthy patients in the study showed "excellent local and systemic tolerance to SYL040012, leading to very positive trial results."
The company added that it will begin a phase I/II study in patients with elevated intraocular pressure "as soon as possible."